pateclizumab

Home
Ligands
pateclizumab

GtoPdb Ligand ID: 9854

Synonyms: MLTA3698A | PRO283698 | RG7416

Comment: Pateclizumab is a humanized anti-lymphotoxin alpha (LTA) monoclonal antibody that is being investigated for anti-inflammatory potential. Peptide sequences for the heavy and light chains of pateclizumab are 100% matches to sequences 106 and 107 that are claimed in Genentech's patent US7923011B2 [1]. Sequences 106 and 107 identify pateclizumab as antibody 2C8.vX as defined in the patent.

Immunopharmacology Comments
Pateclizumab failed to produce significant clinical efficacy in RA patients after 12 weeks of treatment [4], whilst the head-to-head comparator adalimumab did provide clinical benefit in line with previously published results. The role of LTA in RA is reviewed by Hirose et al. (2018) [3].

Immunopharmacology Comments

Pateclizumab failed to produce significant clinical efficacy in RA patients after 12 weeks of treatment [4], whilst the head-to-head comparator adalimumab did provide clinical benefit in line with previously published results.
The role of LTA in RA is reviewed by Hirose et al. (2018) [3].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Rheumatoid arthritis	Disease Ontology: DOID:7148 OMIM: 180300	Pateclizumab failed to show clinical efficacy in patients with active RA after 12 weeks of treatment.	4